Consolidated Revenue Growth
Consolidated revenue of $1.024 billion, up 6.2% year-over-year (organic growth +2.9%).
Segment Revenue Performance
CooperVision revenue $695 million, up 7.6% YoY (organic +3.3%); CooperSurgical revenue $329 million, up 3.3% YoY (organic +2.2%).
Earnings and Margins
Non-GAAP EPS grew 20% to $1.10. Gross margin was 68.1% (benefitting from lighter mix of lower-margin Asia Pac revenue). Operating income increased ~13.9% with operating expenses improving to 41.2% of sales (from 43.6% prior-year).
Free Cash Flow and Capital Allocation
Free cash flow of $159 million in Q1; FY26 free cash flow guidance raised to $600–$625 million and multi-year FCF outlook of >$2.2 billion (FY26–28). Deployed $92 million to share repurchases (1.1M shares) and reduced net debt to $2.4 billion.
Raised Earnings Guidance
Fiscal 2026 EPS guidance raised to $4.58–$4.66 following the Q1 beat and stronger operational performance.
Product Portfolio Strength — MyDay and MiSight
Daily silicone hydrogel lenses grew 7%; MyDay premium portfolio drove double-digit gains in key SKUs (MyDay multifocal, Energys and torics each grew >15%). MiSight (myopia control) grew 23% to $28 million with positive early adoption of MyDay MiSight in EMEA and MiSight in Japan.
Market Share Momentum
CooperVision grew 10% in calendar Q4 vs. market growth of 6%, and for calendar 2025 CooperVision grew 6% vs. market at 5%, marking 18 consecutive years of market share gains.
Operational Synergies and Technology Leverage
Reorganization, IT implementations and AI-enabled tools are producing meaningful synergies — delivering cost efficiencies, improving working capital and enabling reinvestment into sales and marketing.